Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 82

1.

Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer.

Miyamoto H, Altuwaijri S, Cai Y, Messing EM, Chang C.

Mol Carcinog. 2005 Sep;44(1):1-10. Review.

PMID:
16044418
[PubMed - indexed for MEDLINE]
2.

Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.

Ghosh PM, Malik SN, Bedolla RG, Wang Y, Mikhailova M, Prihoda TJ, Troyer DA, Kreisberg JI.

Endocr Relat Cancer. 2005 Mar;12(1):119-34.

PMID:
15788644
[PubMed - indexed for MEDLINE]
Free Article
3.
4.

Akt in prostate cancer: possible role in androgen-independence.

Ghosh PM, Malik S, Bedolla R, Kreisberg JI.

Curr Drug Metab. 2003 Dec;4(6):487-96. Review.

PMID:
14683476
[PubMed - indexed for MEDLINE]
5.

3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells.

Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW, Ward PJ, Chen CS.

Cancer Res. 2004 Feb 15;64(4):1444-51.

PMID:
14973075
[PubMed - indexed for MEDLINE]
Free Article
6.
7.

The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2.

Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS.

J Biol Chem. 2000 Apr 14;275(15):11397-403.

PMID:
10753955
[PubMed - indexed for MEDLINE]
Free Article
8.

Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.

Pfeil K, Eder IE, Putz T, Ramoner R, Culig Z, Ueberall F, Bartsch G, Klocker H.

Prostate. 2004 Feb 15;58(3):259-68.

PMID:
14743465
[PubMed - indexed for MEDLINE]
9.

A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.

Cai Y, Lee YF, Li G, Liu S, Bao BY, Huang J, Hsu CL, Chang C.

Int J Cancer. 2008 Jul 1;123(1):195-201. doi: 10.1002/ijc.23481.

PMID:
18386814
[PubMed - indexed for MEDLINE]
10.
11.

Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents.

Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, Chen CS.

J Natl Cancer Inst. 2002 Dec 4;94(23):1745-57.

PMID:
12464646
[PubMed - indexed for MEDLINE]
Free Article
12.

An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines.

Paliouras M, Diamandis EP.

Biol Chem. 2008 Jun;389(6):773-80. doi: 10.1515/BC.2008.072.

PMID:
18627304
[PubMed - indexed for MEDLINE]
13.

Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells.

St-Germain ME, Gagnon V, Mathieu I, Parent S, Asselin E.

Int J Oncol. 2004 May;24(5):1311-24.

PMID:
15067356
[PubMed - indexed for MEDLINE]
14.

PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.

Kaarbø M, Mikkelsen OL, Malerød L, Qu S, Lobert VH, Akgul G, Halvorsen T, Maelandsmo GM, Saatcioglu F.

Cell Oncol. 2010;32(1-2):11-27. doi: 10.3233/CLO-2009-0487.

PMID:
20203370
[PubMed - indexed for MEDLINE]
15.

HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway.

Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, Hung MC.

Cancer Res. 2000 Dec 15;60(24):6841-5.

PMID:
11156376
[PubMed - indexed for MEDLINE]
Free Article
16.

Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway.

Lee SO, Lou W, Hou M, Onate SA, Gao AC.

Oncogene. 2003 Sep 11;22(39):7981-8.

PMID:
12970746
[PubMed - indexed for MEDLINE]
17.

Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours.

Culig Z, Steiner H, Bartsch G, Hobisch A.

Endocr Relat Cancer. 2005 Jun;12(2):229-44. Review.

PMID:
15947099
[PubMed - indexed for MEDLINE]
Free Article
18.

Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.

Weiss-Messer E, Merom O, Adi A, Karry R, Bidosee M, Ber R, Kaploun A, Stein A, Barkey RJ.

Mol Cell Endocrinol. 2004 May 31;220(1-2):109-23.

PMID:
15196705
[PubMed - indexed for MEDLINE]
19.
20.

Mechanisms of prostate cancer cell survival after inhibition of AR expression.

Cohen MB, Rokhlin OW.

J Cell Biochem. 2009 Feb 15;106(3):363-71. doi: 10.1002/jcb.22022. Review.

PMID:
19115258
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk